Muteins of fibroblast growth factor 21
AssigneeEli Lilly and Company
InventorsChristopher Carl Frye, Lihua Huang, Radmila Micanovic
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel muteins of human fibroblast growth factor-21 with reduced susceptibility for proteolytic degradation when expressed in yeast. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.
Claims9
The mutein of human FGF-21, or a biologically active peptide thereof, comprising the substitution of Leu 153 with Glu or Ile, in combination with the substitution of Ala for Ser 167, in combination with the substitution of a cysteine for leucine 118 and alanine 134 wherein the numbering of the amino acids is based on SEQ ID NO:1.
Dependencies are inferred from the claim text.